Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | GOT1 | P17174 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30413717 | 1.00 | DYRK1A (0.47) | DYRK1AAXLMKNK1MKNK2GOT1 | |
| SCHEMBL31751683 | 0.83 | DYRK1A (0.55) | DYRK1AAXLMKNK1MKNK2GOT1 | |
| SCHEMBL580923 | 0.77 | ADORA1 (0.41) | ADORA2AADORA1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL28433440 | 0.77 | ADORA1 (0.44) | DYRK1AGOT1ADORA2AADORA1ALDH1A1 | |
| SCHEMBL2199804 | 0.74 | CSNK2A1 (0.50) | CSF1RRETPDGFRBPIM1KDR | |
| SCHEMBL31371503 | 0.72 | L3MBTL1 (0.34) | DYRK1AGOT1ADORA2AADORA1ALDH1A1 | |
| SCHEMBL31371610 | 0.71 | IL1B (0.35) | DYRK1AALDH1A1 | |
| SCHEMBL31371639 | 0.69 | SCN9A (0.36) | DYRK1APIM1KMT2A | |
| SCHEMBL28901739 | 0.69 | DYRK1A (0.43) | DYRK1AAXLMKNK1MKNK2ADORA2A | |
| SCHEMBL6684473 | 0.69 | DYRK1A (0.44) | DYRK1AAXLMKNK1MKNK2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111377977-B | 4,7-diaryl thieno [2,3-d ] pyridazine cyclometalated iridium complex and preparation method thereof | 安徽工业大学 | 2023-01-31 | — | — | CN | claimed |
| CN-111377977-A | 4, 7-diaryl thieno [2,3-d ] pyridazine cyclometalated iridium complex and preparation method thereof | 安徽工业大学 | 2020-07-07 | — | — | CN | claimed |
| US-12319701-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250145595-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2025-05-08 | — | — | US | disclosed |
| CN-119798221-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20240409553-A1 | HETEROCYCLIC NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4433480-A1 | HETEROCYCLIC NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-09-25 | — | — | EP | disclosed |
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| CN-118541365-A | Antagonists of muscarinic acetylcholine receptor M4 | 范德堡大学 | 2024-08-23 | — | — | CN | disclosed |
| US-20240228468-A1 | N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | VANDERBILT UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| CN-118234730-A | Heterocyclic NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-1228063-B1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORP (US) | 2009-02-11 | — | — | EP | disclosed |
| EP-1228063-B1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORP (US) | 2009-02-11 | — | — | EP | disclosed |
| EP-2010173-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | Bayer HealthCare AG (DE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007118602-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118602-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2007-10-25 | — | — | WO | disclosed |
| US-20040092740-A1 | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-6689883-B1 | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORPORATION | 2004-02-10 | — | — | US | disclosed |
| EP-1228063-A2 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Bayer Corporation (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001023375-A2 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | NLRP3, NLRP1, PYCARD | DYRK1A 4131/4885AXL 2106/4885MKNK1 503/4885 |
| US-20040092740-A1 | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | VEGFA, PGF, FLT1 | DYRK1A 2704/4885AXL 1060/4885MKNK1 3002/4885 |
| US-12319701-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | DYRK1A 2496/4885AXL 2881/4885MKNK1 2876/4885 |
| US-20240228468-A1 | N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | CHRM5, CHRM1, CHRM2 | DYRK1A 632/4885AXL 1346/4885MKNK1 3981/4885 |
| US-20240409553-A1 | HETEROCYCLIC NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | DYRK1A 4711/4885AXL 2951/4885MKNK1 2195/4885 |
| US-20250145595-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM5 | DYRK1A 1294/4885AXL 1226/4885MKNK1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.